jueves, 20 de noviembre de 2014

Pharma le pone corazón al hígado.../ After hep C cure, companies target next big liver disease market



After hep C cure, companies target next big liver disease market

NEW YORK, Nov 9 (Reuters) -


Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins, which generated more than $30 billion a year in sales at their peak. 

Several companies are working on treatments for hepatitis B, which can be controlled but not yet cured, and for fatty liver conditions caused by rising obesity, which without treatment could affect half of all Americans by 2030, according to the American Liver Foundation (ALF). Some of the drugs will address advanced fibrosis and cirrhosis, which are the scarring that virtually all liver diseases cause without effective treatments. Each of these drugs, once approved, could reach annual sales of as much as $10 billion, industry analysts said. 

 Most of the treatments are now in early Phase I or Phase II clinical trials, with more informative interim data on several expected over the course of the next year. 

Gilead, which was first to market with its hepatitis C cure Sovaldi late last year and has been racking up about $3 billion in sales each quarter, is a solid bet to be among the leaders in the next wave of liver therapies, experts said. 

"The Gilead program is encouraging," said Dr. Naga Chalasani, director of gastroenterology and hepatology at Indiana University Hospital in Indianapolis, who is participating in clinical trials of promising drugs from Gilead and others. 

Drugmakers are working to address the fatty liver disease known as NASH, or nonalcoholic steatohepatitis. Without treatment, NASH can progress to liver-destroying cirrhosis and potentially cancer. 

ALF estimates that non-alcoholic fatty liver disease, including NASH, affects up to 30 percent of people in the United States. It can be caused by bad diets and alcohol abuse, and has also been tied to diabetes. 

"We have no treatment for that condition other than tell a patient they need to lose weight," said Dr. Mauricio Lisker-Melman, director of the hepatology program at Washington University School of Medicine in St Louis. 

 Intercept Pharmaceuticals has attracted the most attention. Just released final data from a mid-stage clinical trial showed its obeticholic acid halted NASH progression and improved liver scarring in primarily moderately ill patients. "For now, no one else has demonstrated an antifibrotic effect in this population, and I believe we are ahead of the pack in that sense," said Intercept Chief Executive Mark Pruzanski. (Más)

Ver también:

Una mezcla de tres nuevos fármacos cura la hepatitis C en trasplantados de hígado
An Interferon-free Antiviral Regimen for HCV after Liver Transplantation

FarmaApp: La Guía de Apps de Farmacia.

Asi se "promociona"...:

Esta guía pretende ser un apoyo para mejorar la salud de los ciudadanos a través de Apps de salud. He hecho una recopilación de las Apps que, en mi opinión, tienen calidad y son útiles de recomendar desde la Farmacia comunitaria porque pueden aportar valor añadido en la mejora de salud o calidad de vida. Para ello he tenido en cuenta las diferentes patologías y situaciones relacionadas con la salud. 

Animo a los farmacéuticos a que utilicen esta guía para mejorar la salud y la calidad de vida de sus clientes, así como, para mejorar la adherencia a los tratamientos y realizar una completa atención farmacéutica aprovechando las nuevas tecnologías. 

Igualmente animo a los pacientes crónicos a que se acostumbren a empezar a utilizar Apps como una nueva herramienta de apoyo y mejora de su salud. Llega la hora de recomendar y "dispensar" Apps de salud. 

Pablo Arriola

Entre las muchas que incluye destacamos..."Genericum"


Esta aplicación presenta los medicamentos genéricos más utilizados actualmente en medicina. Incluye información del grupo farmacéutico al que pertenecen, sus indicaciones terapéuticas y equivalencias en especialidad farmacéutica. Se puede filtrar por grupo farmacéutico y buscar por nombre del medicamento genérico. Genericum es una app de Llar i Salut elaborada por Iboo Mobile. @iBooMobile Es gratuita. Disponible en Google Play y en App Store. (Ver)

miércoles, 19 de noviembre de 2014

Vasella regresa al ruedo...de XBiotech

Daniel Vasella, ancien patron de Novartis, a été nommé au conseil d’administration de l’américain XBiotech, sis au Texas, révèle le Tages-Anzeiger mercredi. Il y retrouvera Rolf Zinkernagel, un autre ancien administrateur du géant pharmaceutique rhénan, de même que Thomas Kündig, directeur de recherches à l’hôpital universitaire de Zurich. 

XBiotech entend procéder d’ici à la fin de l’année à une entrée en bourse, qui devrait lui permettre de lever 100 millions de dollars. 

En février 2013, lâché par les milieux économiques suisses et menacé d’une sortie pitoyable de Novartis, Daniel Vasella avait jeté l’éponge et renoncé au contrat de non-concurrence signé en 2010, qui lui assurait des indemnités pouvant s’élever à 72 millions de francs. L’annonce, tombée deux semaines avant le vote sur l’initiative populaire contre les rémunérations abusives, avait aussi jeté la consternation chez les adversaires de ce texte, également appelé initiative Minder, du nom de son auteur Thomas Minder. Les milieux économiques en particulier, à commencer par l’association faîtière economiesuisse, avaient réagi avec incompréhension.(Ver)

Alcon (Novartis): Jeff George, homme-orchestre

Appelé chez Novartis par Daniel Vasella en 2007, à l’âge de 32 ans, Jeff George est l’un des cadres actuels du groupe pharmaceutique qui connaît le mieux l’entreprise. 

D’abord engagé dans la division pharmaceutique pour développer les marchés émergents, il a ensuite occupé des fonctions dirigeantes dans la division vaccins, aujourd’hui vendue à GlaxoSmithKline, avant de reprendre la tête de Sandoz, secteur des médicaments génériques du groupe bâlois.

C’est là que cet homme-orchestre américain, fan de football à l’européenne à Dallas, a rendu cette division rentable en la profilant dans les biogénériques. 

Il dirige Alcon depuis un peu plus de six mois, où il espère vivre de fortes percées scientifiques et technologiques grâce à un accord particulier avec Google.(Ver)

martes, 18 de noviembre de 2014

South America: Pharma Market New Horizonts / Shanshan Wang*

Ckick sobre imagen para ampliar

Latin America will become increasingly important for pharmaceutical companies who are seeking global expansion. Demand for advanced medicines from the steadily increasing middle class in the region will continue to drive revenue growth for innovative businesses, while improving local healthcare systems will come to rely on an enhanced supply of medical treatments to address the main health problems. 

We forecast that by 2023, medicine expenditure in Latin America will account for over 11% of the global drug market – up from 6% in 2005.

Brazil: 

Set for Success Brazil will continue to be the most attractive market for drug-makers in Latin America. Sales of pharmaceuticals in the country have been resilient to fluctuations in economic activity, which is strongly influenced by commodity prices. As the Brazilian Federal Constitution dictates that access to healthcare is a social right and independent of financial capacity, the government is committed to improving the national standard of healthcare. The majority of the leading foreign manufacturers have a well-established presence in Brazil – over the past few years, Sanofi, with the largest Latin American sales among its global peers, generated over 40% of its Latin American revenue in Brazil alone.

Mexico: 

Full of Promise Mexico's encouraging macro-economic growth prospects, business-friendly operating environment and improving pharma regulatory regime have made it an increasingly attractive market for multinationals. The ageing population, the increasing incidence of chronic diseases and the government's determination to improve healthcare services are other fundamental factors driving market growth. 

While key issues such as the low healthcare spending, the lack of a unified reimbursement system and the absence of widespread private health insurance have hindered the access of innovative medicines in the country, in the long term, healthier fiscal revenue due to the energy sector reforms will encourage the government to further increase public healthcare spending and improve national standards.

Emerging Interest 

Chile's open economy, efficient legal framework, businessfriendly environment and local manufacturers’ strong regional presence have also attracted foreign pharma companies to invest in its local businesses, capitalising on the strong growth in the broader Latin American market. In May 2014, Abbott Laboratories acquired a major Chilean drug-maker, CFR, to boost its generic drug sales, as CFR has a significant presence throughout Latin America. Abbott has been striving to expand its emerging markets presence after launching its spin-off drug business, AbbVie. We believe that local leading healthcare companies in Latin America will become increasingly attractive to multinationals, as the region has become a key target for market expansion.



Risky Business 

Emerging markets have experienced various levels of local currency devaluation against the US dollar in the past few quarters. With the US Federal Reserve tapering off quantitative easing, investors have discarded their local currency holdings, resulting in capital flowing back into developed states. The Argentine Peso and Venezuelan Bolívar have experienced significant depreciation, which has had an immediate negative impact on the performance of multinational pharma companies. Merck, Roche, Sanofi and Novartis have all booked charges tied to these weakened currencies. 

In Venezuela, after the authorities called an 'economic war' against business owners and foreign influences in November 2013, the government has attempted to depict additional drug price cuts as a fight against opportunistic capitalism – especially on essential drugs – of which price controls have been re-introduced since 2003. Nearly 70% of all essential drugs are produced at a loss. Consequently, many manufacturers have opted to halt the commercialisation of such drugs in order to diminish financial losses, resulting in severe drug shortages and the depletion of inventories. 

In Argentina, due to the devaluation of the Peso, the average price of medicines sold through pharmacies has increased dramatically. Some product prices have risen by nearly 50%, as many medicines and active pharmaceutical ingredients are imported to Argentina. The government has tried to negotiate with pharma companies to have drug prices rolled back, and are planning to impose fines on drug-makers that do not comply with the regulation.
 

Sustained Success? 

As foreign drug-makers deepen their ventures in Latin America, pharma companies are more exposed than ever to local political and macro-economic changes. Sustained success will come from more proactive approaches to understand and embrace local trends and developments in each individual market. (Más)


(*) Shanshan Wang is a Pharmaceuticals and Healthcare Analyst at Business Monitor International, a Fitch Group company. She joined in 2011 and is responsible for identifying market entry and expansion opportunities, assessing operational risk, and analysing global corporate growth strategies.

USA: "low-T" problem...deceptive marketing

Deceptive marketing "duped" insurers into paying billions for ineffective and unsafe drugs to treat low testosterone, one claims in Federal Court. 

Medical Mutual of Ohio sued Abbvie, Abbott Laboratories, Solvay America, Eli Lilly and Company, Auxilium Pharmaceutical, Actavis Pharma and various subsidiaries on Wednesdays. 

The complaint comes in the wake of hundreds of product-liability lawsuits against Abbott Labs, the maker of AndroGel, and others over an aggressive disease-awareness campaign that led millions of men to think that their lack of energy was low-testosterone, or "low-T," problem. 

Many men who took AndroGel claim that the drug gave them serious medical problems, including life-threatening cardiac events, strokes and thrombolytic problems. 

Medical Mutual of Ohio, an insurance company, joined the chorus of individual complaints Wednesday with a class action purporting to represent all insurers that paid for the costs of AndroGel, Testopel, Axiron, Androderm and Fortesta Gel

"These TRT [testosterone-replacement therapy] drugs were marketed as part of a decade-long deceptive marketing scheme to transform the male aging process into a curable disease state defendants variously called 'Andropause,' 'ate-onset male hypogonadism,' 'age-related hypogonadism,' or simply 'Low T, which were invented from whole cloth," the 341-page complaint states. 

But the U.S. Food and Drug Administration never approved promotion of the TRT drugs to third-party payors like insurance companies, as well as to patients and physicians, "for 'Andropause' and as a treatment for a host of medical problems,"Medical Mutual says. 

In addition to unapproved, such "off-label" were also ineffective, the complaint says.(Más)

Ver también:

The "Low T" Mouvement / "Selling That New-Man Feeling."

lunes, 17 de noviembre de 2014

Humor...es lunes: Depois de outubro rosa...novembro azul. Hoy 17 de noviembre.




Novembro Azul (Movember) é uma campanha de conscientização realizada por diversas entidades no mês de novembro dirigida a sociedade e aos homens sobre a importância da e do diagnóstico precoce do câncer de próstata e outras doenças masculinas vários países, o Movember é mais do que uma simples campanha de conscientização. 

Ver:

Cock in a Sock © is a fun campaign to raise awareness for male cancers. Celebrando "Movember"...*


Há reuniões entre os homens com o cultivo de bigodes (ao estilo Mario Bros), símbolo da campanha, onde são debatidos, além do câncer de próstata, outras doenças como o câncer de testículos, depressão masculina, cultivo da saúde do homem, entre outros.

O movimento surgiu na Austrália, em 2003, aproveitando as comemorações do Dia Mundial de Combate ao Câncer de Próstata, realizado a 17 de novembro. (Más)

 

Creatividad: Ivermectina / Calox





Brand:
Agency:
Creative Director:

domingo, 16 de noviembre de 2014

Cock in a Sock © is a fun campaign to raise awareness for male cancers. Celebrando "Movember"...*

March 2014 saw the revolutionary craze of the 'no make up selfie' swarm our social media outlets as a way for women to raise both awareness and funds for breast cancer research. This led to what has now become an international campaign founded by James Brown, named Cock in a Sock. 

With 2 people close to him fighting the battle of both testicular and prostate cancer, James saw the opportunity to create a unique way for funds to be raised to research the diseases, as well as awareness and education to be brought to men regarding this very serious subject. He did this by uploading a photograph of his naked self, with only his prized male possession covered by a sock! At the time of uploading, he hashtagged 'Cock in a Sock' and uploaded a side photo of the screen shot where he donated to cancer research. What happened next was an international phenomenon. Hundreds of thousands of people from across the world reached out to James and followed suit by uploading their own photos and donations. 

National and international press contacted him to write articles in support of the campaign, as well as celebrities showing support with uploads and hash tags. Facebook HQ reached out to show their support, and Cancer Research UK thanked James's campaign for helping raise £8 million in conjunction with the separate campaign of the no make up selfies. James is now in the process of registering an official charity 'Get Your Sock Out. 

The charity intends to now create an ongoing way for funds to be raised to help both medical professionals researching ways to prevent/treat the disease of testicular and prostate cancer, awareness to be brought to the subject, and education given regarding ways for men to check their bodies regularly. 

Through our website we hope that you will join forces with us by uploading your own Cock in a Sock photos, along with a donation, and you will also find exciting news fresh from the press, as well as upcoming events hosted by the charity. Not to mention our fantastic range of merchandise to benefit the cause.




Ver también:

Male Cancer Awareness: Mr. Testicles / James Bum 002 / NEAR NAKED MAN/ Campaña contra el cáncer de intestino, próstata y de testículos

 Cientos de hombres ‘envuelven’ su pene en un calcetín y se marcan un ‘selfie’ por una buena causa


(*) Entra en Movember España

sábado, 15 de noviembre de 2014

Robin Williams was on drugs at the time of his death...

“The antidepressant found 
in Williams' toxicology test, 
Mirtazapine (Remeron), 
has 10 drug regulatory agency warnings 
citing suicidal ideation.”


If news headlines were to be believed about the autopsy findings of beloved actor/comedian Robin Williams, who tragically committed suicide nearly two months ago, no drugs were found in his system at the time of his death, as evidenced by headlines from USA Today, NBC News, the BBC and others proclaiming “no alcohol or drugs” were found. These headlines couldn’t be more wrong. 

The medical examiner’s report cites an antidepressant drug was in Williams’ system at the time of his death. The particular antidepressant, Mirtazapine, (also known as Remeron) carries 10 international drug regulatory warnings on causing suicidal ideation. 

According to the autopsy results, not only was Williams under the influence of antidepressant drugs, but the powerful antipsychotic Seroquel was also found at the scene and appears to have been recently taken by Williams. While toxicology tests apparently were negative for the antipsychotic Seroquel, the fact remains that a bottle of Seroquel prescribed to Williams on August 4th, just seven days prior to Williams’ suicide, was missing 8 pills. The Seroquel instructions advise to take one pill per day as needed. Side effects associated with Seroquel include psychosis, paranoid reactions, delusions, depersonalization and suicide attempt.

The question that has to be asked is why the press continues to promote the idea that no drugs were found in Williams’ system? At what point did mind-altering psychiatric drugs, which have side effects rivaling those of heroin or crack cocaine, stop being called drugs?And for those in the press who did “mention” the fact that Williams was found to have antidepressants in his system, the acknowledgement seems to promote the fact that “therapeutic concentrations” of prescription psychiatric drugs “improved his condition and kept him active until his death.” (Más)

Ver también todo Seroquel en PHARMACOSERÍAS

viernes, 14 de noviembre de 2014

Cinema Paradiso: Seré asesinado / Justin Webster




Hace ya más de 4 años en PHARMACOSERÍAS publicamos un serial: 

GUATEMALA: Sexo, mentiras, medicinas y cinta de videotape.(VI)...


Ahora podemos ver el documental que termina de esclarecer los hechos violentos ocurridos en Guatemala y en los que los hermanos Francisco José y José Estuardo Valdés Paiz, prestigiosos empresarios de la industria farmacéutica local e íntimos amigos de Rosenberg, fueron acusados por la Comisión Internacional contra la Impunidad en Guatemala (Cicig) de haber contratado al grupo de sicarios que el 10 de mayo del 2009 asesinaron al abogado en un barrio residencial del sur de la capital.

"Seré asesinado" retrata la oscura realidad del asesinato del abogado guatemalteco Rodrigo Rosenberg. Un caso que dio la vuelta al mundo a través del vídeo que la víctima grabó antes de su muerte donde denunciaba su inminente asesinato en manos del presidente del país, y que tuvo una enorme viralidad en Youtube. Una historia de asesinato, amor e intrigas políticas que se desatan cuando este carismático abogado, muerto a tiros en la calle, apareció en YouTube prediciendo su propia muerte y nombrando a los culpables.  

Ver documental (completo)

Ver también: 
El caso Rosenberg, en la pantalla grande

Palabras: "Bitcoin"

City of words/V.Acconci
Slide: F.Comas "Lo que el tiempo se llevó" De galernas a ciclogénesis en el entorno farmacéutico http://slidesha.re/1nN1FnS

Las bitcoins son una moneda puramente digital que podría revolucionar la forma en la que entendemos el dinero en el mundo. En este excelente video realizado por Duncan Elms podemos apreciar la genialidad de la creación de esta moneda, además de disfrutar de la poesía electrónica de la información: los bitcoins llevan la moneda a convertirse en un tipo de arte digital (mandalas algorítmicos que giran en el ciberespacio).


El bitcoin es una moneda electrónica, descentralizada específicamente diseñada para el mundo digital y el intercambio P2P. Criptografías y señales digitales generan una divisa conforme a un algoritmo que registra todas las transacciones pero de manera anónima. A diferencia de las monedas como el dólar, no existe una Reserva Federal con la facultad de imprimir dinero casi ilimitadamente; los bitcoins se generan a través de un proceso de minería matemática y están limitados a solo 21 millones de bitcoins. En este sentido aunque son una economía puramente virtual reflejan en mayor medida el valor del mundo real que las mismas divisas físicas. “Por qué depositar toda nuestra confianza en los bancos. Ellos nos piden todos nuestros detalles y solo falta que nos saquen una muestra de sangre. Es mejor confiar en un código matemático encriptado, con un diseño elegante y que no pide almacenar nuestra identidad”, afirma Amir Taaki, cofundador de Bitcoin Consultancy.


Los bitcoins ya son utilizados por WikiLeaks y WordPress, además de ser la moneda del internet profundo, o Tor, donde pueden ser usados para comprar drogas ilegales en sitios como Silk Road (una de las críticas que se hace a los bitcoins, a mayor libertad: mayor responsabilidad). En Canadá se está desarrollando un sistema financiero local claramente inspirado en los bitocoins: y quizás esta sea su mayor aportación, más que convertirse en una moneda global de espíritu open-source, inspirar a la creación de nuevas monedas del mismo estilo y resgignificar cómo vivimos el dinero. Aunque tuvieron una fuerte caída en su valor este mes,  los bitcoins sin duda presentan una marcada tendencia a la alza.